{"id":8606,"date":"2025-09-13T15:18:04","date_gmt":"2025-09-13T12:18:04","guid":{"rendered":"https:\/\/jordan-cardiac.org\/?p=8606"},"modified":"2025-09-13T15:18:04","modified_gmt":"2025-09-13T12:18:04","slug":"asymptomatic-severe-aortic-stenosis-key-insights-esc-2025","status":"publish","type":"post","link":"https:\/\/jordan-cardiac.org\/en\/asymptomatic-severe-aortic-stenosis-key-insights-esc-2025\/","title":{"rendered":"Asymptomatic Severe Aortic Stenosis \u2013 Key Insights (ESC 2025)"},"content":{"rendered":"
Asymptomatic Severe Aortic Stenosis \u2013 Key Insights (ESC 2025)<\/div>\n
1. Background<\/span><\/div>\n
\u2022 Severe AS can remain silent for years.<\/span><\/div>\n
\u2022 Once symptoms appear, prognosis worsens rapidly.<\/span><\/div>\n
\u2022 Debate continues: Should we intervene early or wait until symptoms develop?<\/span><\/div>\n
2. EARLY-TAVR Trial (NEJM 2025, presented at ESC 2025)<\/span><\/div>\n
\u2022 ~900 patients with asymptomatic severe AS randomized to:<\/span><\/div>\n
\u2022 Early TAVR vs Clinical surveillance.<\/span><\/div>\n
\u2022 Findings:<\/span><\/div>\n
\u2022 Early TAVR reduced the combined risk of death, stroke, and unplanned CV hospitalizations.<\/span><\/div>\n
\u2022 Main benefit: fewer hospitalizations and lower stroke risk.<\/span><\/div>\n
\u2022 Mortality difference: not yet significant.<\/span><\/div>\n
3. Meta-analyses (JACC 2025, G\u00e9n\u00e9reux et al.)<\/span><\/div>\n
\u2022 Early AVR (surgical or transcatheter) consistently lowers stroke and HF admissions.<\/span><\/div>\n
\u2022 Impact on overall survival remains under investigation.<\/span><\/div>\n
4. ESC 2025 Update<\/span><\/div>\n
\u2022 New guidelines give Class IIa recommendation for early intervention in selected asymptomatic severe AS patients at low procedural risk.<\/span><\/div>\n
\u2022 Key message: \u201cEarly action may prevent irreversible heart damage.\u201d<\/span><\/div>\n
5. Patient Selection Rules \u2013 When to Consider Early Intervention<\/span><\/div>\n
\u2022 Severe high-gradient AS confirmed (AVA \u22641.0 cm\u00b2, mean gradient \u226540 mmHg, Vmax \u22654.0 m\/s).<\/span><\/div>\n
\u2022 Truly asymptomatic (no angina, syncope, or HF; confirm with exercise testing if needed).<\/span><\/div>\n
\u2022 Low procedural risk (suitable surgical\/TAVR candidate without prohibitive comorbidities).<\/span><\/div>\n
\u2022 Early signs of cardiac damage (LVEF <50%, LV hypertrophy\/fibrosis, rising BNP\/troponin).<\/span><\/div>\n
\u2022 Rapid progression (Vmax increase \u22650.3 m\/s\/year or worsening echo findings).<\/span><\/div>\n
\u2022 Age & anatomy fit (TAVR often for older patients; surgery for younger\/low-risk).<\/span><\/div>\n
6. Take-home Message<\/span><\/div>\n
\u2022 Asymptomatic severe AS is no longer a passive \u201cwatch-and-wait\u201d condition.<\/span><\/div>\n
\u2022 Early TAVR\/AVR is reasonable in well-selected patients to reduce hospitalizations and stroke, and to protect the heart before damage is irreversible.<\/span><\/div>\n
\u2022 Careful patient selection remains the cornerstone.<\/span><\/div>\n
<\/div>\n
https:\/\/www.nejm.org\/doi\/abs\/10.1056\/NEJMoa2405880<\/a><\/div>\n
<\/div>\n","protected":false},"excerpt":{"rendered":"

Asymptomatic Severe Aortic Stenosis \u2013 Key Insights (ESC 2025) 1. Background \u2022 Severe AS can remain silent for years. \u2022 Once symptoms appear, prognosis worsens rapidly. \u2022 Debate continues: Should we intervene early or wait until symptoms develop? 2. EARLY-TAVR Trial (NEJM 2025, presented at ESC 2025) \u2022 ~900 patients with asymptomatic severe AS randomized […]<\/p>\n","protected":false},"author":145,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-8606","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/8606","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/users\/145"}],"replies":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/comments?post=8606"}],"version-history":[{"count":1,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/8606\/revisions"}],"predecessor-version":[{"id":8607,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/8606\/revisions\/8607"}],"wp:attachment":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/media?parent=8606"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/categories?post=8606"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/tags?post=8606"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}